RedHill Biopharma (NASDAQ:RDHL) Ltd. has announced that the US Patent and Trademark Office (USPTO) has issued the company with two new patents for its drugs, opaganib and RHB-104.
The first covers the use of opaganib for treating Ebola virus disease, with patent protection until 2035, and the other covers RHB-104 for treating bacterial infections, with protection through 2029.
READ: RedHill Biopharma completes treatment and follow-up in the 475-patient global Phase 2/3 COVID-19 study with opaganib
In a statement, Danielle T. Abramson, Ph.D., SVP, Global Head of Intellectual Property at RedHill commented: "Opaganib's potent activity against several single-stranded RNA viruses positions it as a potential treatment for many viral diseases, including COVID-19 and other viruses that are the origin of devastating epidemics.
"Ebola virus disease remains a major risk with recent recurring outbreaks. Opaganib has already demonstrated positive results from non-clinical studies in Ebola, and RedHill is committed to continuing its development as a potential treatment for this devastating disease. In addition, we continue to evaluate the potential development path to approval of RHB-104 for Crohn's disease."
Opaganib is also under development for coronavirus (COVID-19), with a 475-patient global Phase 2/3 study in patients hospitalized with severe COVID-19 with patient treatment and follow-up recently completed and top-line results upcoming.
In parallel, opaganib is also being studied in Phase 2 U.S. studies in cholangiocarcinoma and prostate cancer, as well as development programs for other indications.
The MAP US randomized, double-blind, placebo-controlled first Phase 3 study with oral RHB-104 for Crohn's disease successfully met both its primary endpoint and its key secondary endpoints and presented the broad benefit of RHB-104 as an add-on therapy to standard-of-care treatments for Crohn's disease, including anti-TNFs. Future development path to approval is being explored.
RedHill Biopharma is a specialty biopharmaceutical company primarily focused on gastrointestinal and infectious diseases.
Contact the author at jon.hopkins@proactiveinvestors.com
Disclaimer: This content has been provided pursuant to an agreement under which RedHill Biopharma pays an annual fee to the publisher. (https://www.proactiveinvestors.com/pages/terms)